SCHEMBL8969441

SCHEMBL8969441

CCC(C(=O)O)c1ccccc1C(C)=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.41
LMNA P02545 5/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPT P10636 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
BCHE P06276 1/20 0.38
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 4/20 0.37
CYP1A2 P05177 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
AKR1C3 P42330 3/20 0.36
AKR1C2 P52895 3/20 0.36
AKR1C1 Q04828 1/20 0.36
HPGD P15428 1/20 0.36
SRC P12931 1/20 0.36
PTGS1 P23219 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5508368 0.87 POLB (0.50) POLBLMNAHSD17B10MAPTBCHE
SCHEMBL28209564 0.83 AKR1C3 (0.47) LMNAHSD17B10MAPTALDH1A1SMN1; SMN2
SCHEMBL10949570 0.81 ALDH1A1 (0.47) LMNAMAPTALDH1A1TSHR
SCHEMBL10943238 0.81 ALDH1A1 (0.47) LMNAMAPTALDH1A1TSHR
SCHEMBL10944016 0.81 ALDH1A1 (0.47) LMNAMAPTALDH1A1TSHR
SCHEMBL10942047 0.81 ALDH1A1 (0.47) LMNAMAPTALDH1A1TSHR
SCHEMBL28872151 0.80 USP2 (0.43) POLBLMNAMAPTL3MBTL1ALDH1A1
SCHEMBL15877038 0.79 LMNA (0.38) POLBLMNAHSD17B10MAPTBCHE
SCHEMBL4071095 0.78 TSHR (0.57) POLBLMNAHSD17B10ALDH1A1KDM4E
SCHEMBL4062734 0.78 LMNA (0.41) POLBLMNAHSD17B10ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240209355-A1 NUCLEIC ACID BINDING PROTEIN FORMULATIONS AND USES THEREOF SPOTLIGHT THERAPEUTICS 2024-06-27 US disclosed
WO-2022140795-A2 NUCLEIC ACID BINDING PROTEIN FORMULATIONS AND USES THEREOF SPOTLIGHT THERAPEUTICS (US) 2022-06-30 WO disclosed
WO-2022056231-A1 COMPOSITIONS AND METHODS FOR SCREENING CELL INTERNALIZING AGENTS SPOTLIGHT THERAPEUTICS (US) 2022-03-17 WO disclosed
CN-114040775-A Targeted active gene editing agents and methods of use 光点治疗公司 2022-02-11 CN disclosed
CN-114026123-A Targeted active gene editing agents and methods of use 光点治疗公司 2022-02-08 CN disclosed
EP-3941943-A1 TARGETED ACTIVE GENE EDITING AGENT AND METHODS OF USE Spotlight Therapeutics (US) 2022-01-26 EP disclosed
EP-3941515-A1 TARGETED ACTIVE GENE EDITING AGENT AND METHODS OF USE Spotlight Therapeutics (US) 2022-01-26 EP disclosed
US-20220010337-A1 TARGETED ACTIVE GENE EDITING AGENT AND METHODS OF USE SPOTLIGHT THERAPEUTICS (US) 2022-01-13 US disclosed
US-20220002695-A1 TARGETED ACTIVE GENE EDITING AGENT AND METHODS OF USE SPOTLIGHT THERAPEUTICS (US) 2022-01-06 US disclosed
WO-2021062201-A1 COMPOSITIONS AND METHODS FOR NUCLEOPROTEIN TARGETING AND EXPRESSION SPOTLIGHT THERAPEUTICS (US) 2021-04-01 WO disclosed
WO-2020198151-A1 TARGETED ACTIVE GENE EDITING AGENT AND METHODS OF USE SPOTLIGHT THERAPEUTICS (US) 2020-10-01 WO disclosed
WO-2020198160-A1 TARGETED ACTIVE GENE EDITING AGENT AND METHODS OF USE SPOTLIGHT THERAPEUTICS (US) 2020-10-01 WO disclosed
EP-0699209-A1 PROCESSES AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-03-06 EP disclosed
WO-1994026779-A1 PROCESSES AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-11-24 WO disclosed